Cardium Therapeutics, Inc. Form 8-K July 15, 2008

#### **UNITED STATES**

#### SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

# FORM 8-K

#### **CURRENT REPORT**

pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

DATE OF REPORT (Date of earliest event reported): July 14, 2008

001-33635

(Commission file number)

# CARDIUM THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware (State of incorporation)

27-0075787 (IRS Employer Identification No.)

3611 Valley Centre Drive, Suite 525

San Diego, California 92130 (Address of principal executive offices)

(858) 436-1000

(Registrant s telephone number)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

<sup>&</sup>quot; Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

# Edgar Filing: Cardium Therapeutics, Inc. - Form 8-K

- " Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

### Edgar Filing: Cardium Therapeutics, Inc. - Form 8-K

#### ITEM 8.01 OTHER EVENTS.

On July 14, 2008, Cardium Therapeutics, Inc. ( Cardium ) and its operating unit InnerCool Therapies, Inc. ( InnerCool ) issued a press release announcing that InnerCool s new RapidBlue System had obtained CE Mark for commercial sale in Europe and UL certification. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.

#### ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

(d) Exhibits.

99.1 Press Release of Cardium issued on July 14, 2008.

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

### CARDIUM THERAPEUTICS, INC.

Date: July 14, 2008 By: /s/ Christopher J. Reinhard

Christopher J. Reinhard Chief Executive Officer